Renal Cell CarcinomaYKSTNCT05005195
Yorkshire Kidney Screening Trial
A study testing Low dose abdominal computed tomography scan in people with Renal Cell Carcinoma, run by University of Leeds at 1 site in United Kingdom.
Trial summary
Kidney cancer is the 8th most common cancer in Yorkshire. It has a poor survival rate, with only 6 out of 10 patients diagnosed with kidney cancer still alive after 5 years. This is partly because many people with kidney cancer don't have any symptoms. Read more about this study
- Who is it for?
- Ages 55 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Renal Cell Carcinoma
- What is being tested?
- Low dose abdominal computed tomography scan
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,850 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 10 May 2021to 30 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- As YKST will involve only consenting participants of T2 round of YLST the same inclusion criteria for the YLST Lung Health Check at the T0 stage will be used for YKST, namely:
- High risk for lung cancer as defined by one of the three criteria:
- 30 pack year history of smoking and current smoker or quit within the last 15 years (USPSTF criteria).
- Lung cancer risk of ≥1.51% over 6 years as calculated by the PLCOM2012 score.
- Lung cancer risk of ≥5% over 5 years as calculated by the LLPv2. score.
Who cannot join
- Have undergone CT Thorax within the previous 6 months
- Unable to provide informed consent to study
- Unable to have a chest or abdominal non-contrast CT scan
- Previous diagnosis of kidney cancer
- Have undergone abdominal CT scan in previous 6 months
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Leads Teaching Hospitals Trust
Leeds, Yorkshire, LS1 3EX
About this study
Official title: Yorkshire Kidney Screening Trial (YKST): a Feasibility Study of Adding Non-contrast Abdominal CT Scan to Chest CT Scan Undertaken in the YLST Randomised Controlled Trial of Community-based CT Screening for Lung Cancer in an at Risk Population to Screen for RCC and Other Abdominal Malignancies
Kidney cancer is the 8th most common cancer in Yorkshire. It has a poor survival rate, with only 6 out of 10 patients diagnosed with kidney cancer still alive after 5 years. This is partly because many people with kidney cancer don't have any symptoms. In some of these people, kidney cancer is only found by chance during investigations for other reasons. In others, it is often not diagnosed until the disease has passed the point at which we can easily cure it.
Screening for kidney cancer has the potential to pick up these cancers earlier and increase the number of people who can be cured. The Yorkshire Lung Screening Trial offers people aged 55-80 with a history of smoking a CT scan as part of a lung health check. This group of people is also at increased risk of developing kidney cancer. Our new study, the Yorkshire Kidney Screening Trial, will piggyback on this trial to offer an extra CT scan for kidney cancer. The extra scan will take 10 seconds. By the end of the study we will understand whether it is workable to roll this out more widely and whether people take up this extra scan.
Read the detailed description
Background to YLST and link with YKST
YKST will be offered to participants of YLST. In brief, YLST is a community-based screening programme funded by Yorkshire Cancer Research which uses mobile units across Leeds through a Zelen's design study, allowing assessment of the overall effect of screening Yorkshire people who are current smokers or ex-smokers and therefore at high-risk for lung cancer. YLST is one of the World's largest lung cancer screening trials and nesting YKST within this on-going trial provides a unique opportunity to both add value to this existing trial and provide much needed data relating to future RCC screening.
In YLST, ~45,000 people were invited to participate in the study with 6,892 eventual participants estimated to attend for the first of two rounds of low-dose CT (LDCT) screening (called T0 and T2 respectively). To identify eligible individuals, General Practices within the Leeds CCG area provided consent for interrogation of their Primary Care databases
At the first Lung Health Check (T0) relevant clinical and demographic information were collected and participants were offered a LDCT scan either immediately or to return another day at their preference. Two years later the participants who attended for an initial Lung Health Check are invited back for a follow-up Lung Health Check (T2) which includes a second LDCT scan. In YKST we are asking participants in this T2 round of YLST, from 10 May 2021 to 31 Oct 2022, to undergo an abdominal CT scan in addition to the repeated CT chest.
Participant pathway and detailed logistics
There are 2 major elements to the logistics of YKST: 1) Obtaining the abdominal CT scan. From invitation to completion of the CT scan, the existing YLST infrastructure will be used on the YLST van. 2) Downstream processes from the scan. Reporting of the CT scan, informing participants of results and dealing with anomalies. These are new YKST specific processes, separate to YLST. Invitation YLST participants will receive a telephone call to book a T2 round appointment. Following this they will receive an appointment letter. If the participant is not available after 2 attempted telephone calls, they are sent a pre-booked appointment.
Consent
On arriving on the YLST van the potential participants will watch the YLST T2 introduction video. Following the YLST T2 introduction video the YKST PIS video will play, this will have been mentioned to YLST participants by van staff on arrival . They will then have the YLST consultation in a private consultation room. After completing the YLST components, they will be asked if they wish to participate in YKST. For those wishing to take part, written consent will be taken whilst in the consultation room and a small number of extra RCC specific questions will be.
Those not wishing to take part will also be asked to give their reasons for declining and asked if they consent to be contacted by a University of Cambridge researcher to discuss taking part in a qualitative interview about their reasons for declining.
Those wishing to have the additional scan will also be asked if they consent to be contacted by a University of Cambridge researcher to discuss taking part in a qualitative research interview about reasons for agreeing to participate. Participants consenting to be contacted by the research team about an interview (those wishing to have the additional scan and those declining the scan) will be sent a separate PIS and a consent form and asked to contact the team if they would like to take part. A member of the research team will then contact them to arrange a convenient time for a telephone or remote video interview. Those taking part will be asked to sign the consent form and send this back to the research team in a stamped addressed envelope, or sign it electronically. In case there is a delay in this process, possibly due to the COVID19 pandemic, verbal consent will also be taken over the telephone at the start of the interview.
All healthcare professionals involved in the screening process will also be invited by the research team to take part in an interview about the acceptability of the combined approach and the logistics. They will be provided with a PIS and consent form and consent taken as for screening participants above.
CT scanning protocol and reporting
Following confirmation that the participant has not has an abdominal CT scan within the previous 6 months, scans will be ordered by the YKST nurse research team or research fellow. We have designed a clear risk mitigation process to ensure that if a participant wishes to continue with lung screening as part of YLST but does not want to participate in the YKST component, that they do not get the abdominal CT scan. The mechanism for this is that a hard copy of the Kidney Screening CT request form will only be printed once participants have signed the YKST consent form. As an additional check the radiographers will be asked to sign the request form to indicate that they have seen the YKST consent form before proceeding to the additional kidney screening scan. This will act as an additional prompt for the radiographer team to ensure that the correct screening protocols are used.
The abdominal CT scan will be performed immediately following the CT chest for YLST, the patient will remain lying the CT scanner gantry and the abdominal CT will take a further 10 seconds to be performed.
Management of screening results
The Lead Consultant Radiologist and the YKST Principal Investigator (a Consultant Urologist)at Leeds Teaching Hospitals NHS Trust have developed a series of pathways for flagging in the CT report, based on: 1 - Normal; 2 - benign urological finding; 3 - Indeterminate benign finding (i.e. cholecystitis/pancreatitis); 4 Possible malignancy outside renal tract (2 week wait referral) or AAA (referral to vascular surgery); 5 - Possible renal/urological cancer (2 week wait referral).
The PI will work with the nurse practitioner and administration support employed by YKST for the duration of the scanning period so that they can inform the patients of results and refer patients to the appropriate other specialities: e.g. vascular and HPB surgery There are no further visits of assessments for participants of YKST.
Qualitative interviews and ethnography
We will conduct semi-structured qualitative telephone or remote video interviews within 3 months of the initial study invitation with a purposive sample of both participants who take up the additional abdominal CT scan and those who decline the additional scan. The interviews will explore their views on the acceptability of the combined screening approach, the consent process, the information provided about the additional scan, and their reasons for accepting or declining the scan. We will also explore potential psychological harms, for example, increased anxiety or worry related to the additional scan or the information provided about kidney cancer and other potential abdominal findings. We will draw on the principles of information power when deciding when to cease data collection but anticipate interviewing up to 40 participants. We will purposefully sample participants with the aim to include approximately 20 who took up the additional scan and 20 who did not and to include participants with a range of ages, sex, and abdominal findings. Interviews will be recorded and transcribed for analysis. We expect interviews to last between 30-45 minutes.
To assess the study processes, including ordering the scans, obtaining consent, ensuring only participants consenting to the additional abdominal scan receive it, performing, reporting and reviewing the additional scans and feeding back the results, from the perspective of the healthcare professionals we will also conduct telephone/video link interviews with key individuals involved in the screening pathway. These will include CTAs, research nurses, radiographers, radiologists and the triaging urologist. The interview schedule will cover their views on all stages of the pathway relevant to them.
To explore in more detail the consent and scanning process on the screening vans, we will also conduct an ethnographic study with a researcher spending time on the vans observing the patient flow and processes. The field notes from these observations will be combined with the analysis of the interview data to enable us to identify aspects that worked well and any challenges or potential safety concerns within the proposed combined screening pathway in order to inform a future RCT.
- Conditions
- Renal Cell Carcinoma
- Being tested
- Low dose abdominal computed tomography scan
- Keywords
- Screening, Feasibility study
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low dose abdominal computed tomography scanRadiation
A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
| Study group | Role | What they receive |
|---|---|---|
| Abdominal CT Scan | Other | A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer. Receives: Radiation: Low dose abdominal computed tomography scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of individuals who take up the offer of an abdominal CT scan
The proportion of individuals attending the T2 round of YLST who take up the offer of an abdominal CT scan
Measured: At the end of the 18 month recruitment period
The acceptability of the combined lung and RCC screening approach to participants
The acceptability to participants of combined lung and RCC screening by non-contrast CT scanning - ascertained by interviews
Measured: On completion of the patient interview analysis - by the end of the 18 month recruitment period
The acceptability of the combined lung and RCC screening approach to healthcare professionals
The acceptability to healthcare professionals involved in the screening of combining RCC screening by non-contrast CT scanning with lung cancer screening - ascertained by interviews
Measured: On completion of the health care professional interview analysis - by the end of the 18 month recruitment period
The additional time required for the combined screening approach
The additional time required for the combined screening approach, including the time to provide information, consent participants, and perform the lengthier CT scan, the time needed by radiologists for reporting the CT scans, and the additional time to review abdominal CT findings
Measured: On completion of the study process observation analysis - by the end of the 18 month recruitment period
Secondary outcomes (5)
Estimate of the prevalence of RCC
The proportion of participants found to have an RCC to provide an estimate of the prevalence of RCC found on non-contrast CT screening in 55-80y smokers and ex-smokers
Measured: At the end of the 18 month recruitment period
The stage distribution of all RCCs identified, reported as cancer findings with TNM
The stage distribution of RCC identified through non-contrast CT screening, reported as cancer findings with TNM
Measured: At the end of the 18 month recruitment period
The proportion of participants found to have incidental renal findings
The proportion of participants found to have incidental renal findings (cysts, anatomical variants) on non-contrast CT scanning
Measured: At the end of the 18 month recruitment period
The proportion of participants with non-renal findings
The proportion of participants with non-renal findings i.e. abdominal aortic aneurysms, pancreatic and liver lesions on non-contrast CT scanning
Measured: At the end of the 18 month recruitment period
Estimation of the incidence of RCC
The proportion of RCCs found on the upper pole of participants in T2 who did not have them found in T0 round, to estimate the incidence of RCC over sequential non-contrast CT scans (n.b. lesions in the upper pole of the kidney only)
Measured: At the end of the 18 month recruitment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2021
- Study start10 May 2021
- Primary completion30 Apr 2023 (estimated)
- Study completion30 Apr 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Renal Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A non-randomised feasibility study of adding non-contrast CT scanning of the abdomen to the CT chest undertaken in the T2 round of YLST. YLST is a two-arm, (1:1) implementation study using a single-consent Zelen's randomised controlled design. Participants have already been randomised to intervention (invitation to an initial telephone-based riskassessment and then, if eligible, for a Lung Health Check (LHC) which is carried out on a mobile van and incorporates LDCT scanning for lung cancer) or usual care (no invitation).
- Masking
- None (open label)
- Enrolment
- 5,850 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Leeds
- Sponsor type
- University, hospital or other
- Collaborators
- University of Cambridge, Yorkshire Cancer Research, The Leeds Teaching Hospitals NHS Trust
- Responsible party
- Principal investigator, Professor Grant Stewart, University of Leeds
- Investigators
- Grant D Stewart, Principal investigator, University of Cambridge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05005195
- Sponsor's protocol ID
- 290336
- Acronym
- YKST
- Status last verified
- Nov 2022
- First submitted
- 4 Aug 2021
- Last updated
- 2 Nov 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Thomas C, Heathcote L, Sun Y, Callister MEJ, Kitt J, Rossi SH, Shinkins B, Usher-Smith JA, Whyte S, Stewart GD; YKST Study Group. Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England. Br J Cancer. 2025 Aug;133(2):239-247. doi: 10.1038/s41416-025-03043-z. Epub 2025 May 14.
PubMed 40369122Usher-Smith JA, Masson G, Godoy A, Burge SW, Kitt J, Farquhar F, Cartledge J, Kimuli M, Burbidge S, Crosbie PAJ, Eckert C, Hancock N, Iball GR, Rogerson S, Rossi SH, Smith A, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. Acceptability of adding a non-contrast abdominal CT scan to screen for kidney cancer and other abdominal pathology within a community-based CT screening programme for lung cancer: A qualitative study. PLoS One. 2024 Jul 1;19(7):e0300313. doi: 10.1371/journal.pone.0300313. eCollection 2024.
PubMed 38950010Usher-Smith JA, Godoy A, Burge SW, Burbidge S, Cartledge J, Crosbie PAJ, Eckert C, Farquhar F, Hammond D, Hancock N, Iball GR, Kimuli M, Masson G, Neal RD, Rogerson S, Rossi SH, Sala E, Smith A, Sharp SJ, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. BMJ Open. 2022 Sep 20;12(9):e063018. doi: 10.1136/bmjopen-2022-063018.
PubMed 36127097
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Yorkshire Kidney Screening Trial (YKST): a Feasibility Study of Adding Non-contrast Abdominal CT Scan to Chest CT Scan Undertaken in the YLST Randomised Controlled Trial of Community-based CT Screening for Lung Cancer in an at Risk Population to Screen for RCC and Other Abdominal Malignancies
- ClinicalTrials.gov ID
- NCT05005195
- Acronym / sponsor ID
- YKST / 290336
- Conditions
- Renal Cell Carcinoma
- Keywords
- Screening, Feasibility study
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 5,850 participants (estimated)
- Lead sponsor
- University of LeedsUniversity, hospital or other
- Collaborators
- University of Cambridge, Yorkshire Cancer Research, The Leeds Teaching Hospitals NHS Trust
- Study start
- 10 May 2021 (actual)
- Primary completion
- 30 Apr 2023 (estimated)
- Study completion
- 30 Apr 2023 (estimated)
- First posted
- 13 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Kidney cancer is the 8th most common cancer in Yorkshire. It has a poor survival rate, with only 6 out of 10 patients diagnosed with kidney cancer still alive after 5 years. This is partly because many people with kidney cancer don't have any symptoms. In some of these people, kidney cancer is only found by chance during investigations for other reasons. In others, it is often not diagnosed until the disease has passed the point at which we can easily cure it.
Screening for kidney cancer has the potential to pick up these cancers earlier and increase the number of people who can be cured. The Yorkshire Lung Screening Trial offers people aged 55-80 with a history of smoking a CT scan as part of a lung health check. This group of people is also at increased risk of developing kidney cancer. Our new study, the Yorkshire Kidney Screening Trial, will piggyback on this trial to offer an extra CT scan for kidney cancer. The extra scan will take 10 seconds. By the end of the study we will understand whether it is workable to roll this out more widely and whether people take up this extra scan.
Detailed description
Background to YLST and link with YKST
YKST will be offered to participants of YLST. In brief, YLST is a community-based screening programme funded by Yorkshire Cancer Research which uses mobile units across Leeds through a Zelen's design study, allowing assessment of the overall effect of screening Yorkshire people who are current smokers or ex-smokers and therefore at high-risk for lung cancer. YLST is one of the World's largest lung cancer screening trials and nesting YKST within this on-going trial provides a unique opportunity to both add value to this existing trial and provide much needed data relating to future RCC screening.
In YLST, ~45,000 people were invited to participate in the study with 6,892 eventual participants estimated to attend for the first of two rounds of low-dose CT (LDCT) screening (called T0 and T2 respectively). To identify eligible individuals, General Practices within the Leeds CCG area provided consent for interrogation of their Primary Care databases
At the first Lung Health Check (T0) relevant clinical and demographic information were collected and participants were offered a LDCT scan either immediately or to return another day at their preference. Two years later the participants who attended for an initial Lung Health Check are invited back for a follow-up Lung Health Check (T2) which includes a second LDCT scan. In YKST we are asking participants in this T2 round of YLST, from 10 May 2021 to 31 Oct 2022, to undergo an abdominal CT scan in addition to the repeated CT chest.
Participant pathway and detailed logistics
There are 2 major elements to the logistics of YKST: 1) Obtaining the abdominal CT scan. From invitation to completion of the CT scan, the existing YLST infrastructure will be used on the YLST van. 2) Downstream processes from the scan. Reporting of the CT scan, informing participants of results and dealing with anomalies. These are new YKST specific processes, separate to YLST. Invitation YLST participants will receive a telephone call to book a T2 round appointment. Following this they will receive an appointment letter. If the participant is not available after 2 attempted telephone calls, they are sent a pre-booked appointment.
Consent
On arriving on the YLST van the potential participants will watch the YLST T2 introduction video. Following the YLST T2 introduction video the YKST PIS video will play, this will have been mentioned to YLST participants by van staff on arrival . They will then have the YLST consultation in a private consultation room. After completing the YLST components, they will be asked if they wish to participate in YKST. For those wishing to take part, written consent will be taken whilst in the consultation room and a small number of extra RCC specific questions will be.
Those not wishing to take part will also be asked to give their reasons for declining and asked if they consent to be contacted by a University of Cambridge researcher to discuss taking part in a qualitative interview about their reasons for declining.
Those wishing to have the additional scan will also be asked if they consent to be contacted by a University of Cambridge researcher to discuss taking part in a qualitative research interview about reasons for agreeing to participate. Participants consenting to be contacted by the research team about an interview (those wishing to have the additional scan and those declining the scan) will be sent a separate PIS and a consent form and asked to contact the team if they would like to take part. A member of the research team will then contact them to arrange a convenient time for a telephone or remote video interview. Those taking part will be asked to sign the consent form and send this back to the research team in a stamped addressed envelope, or sign it electronically. In case there is a delay in this process, possibly due to the COVID19 pandemic, verbal consent will also be taken over the telephone at the start of the interview.
All healthcare professionals involved in the screening process will also be invited by the research team to take part in an interview about the acceptability of the combined approach and the logistics. They will be provided with a PIS and consent form and consent taken as for screening participants above.
CT scanning protocol and reporting
Following confirmation that the participant has not has an abdominal CT scan within the previous 6 months, scans will be ordered by the YKST nurse research team or research fellow. We have designed a clear risk mitigation process to ensure that if a participant wishes to continue with lung screening as part of YLST but does not want to participate in the YKST component, that they do not get the abdominal CT scan. The mechanism for this is that a hard copy of the Kidney Screening CT request form will only be printed once participants have signed the YKST consent form. As an additional check the radiographers will be asked to sign the request form to indicate that they have seen the YKST consent form before proceeding to the additional kidney screening scan. This will act as an additional prompt for the radiographer team to ensure that the correct screening protocols are used.
The abdominal CT scan will be performed immediately following the CT chest for YLST, the patient will remain lying the CT scanner gantry and the abdominal CT will take a further 10 seconds to be performed.
Management of screening results
The Lead Consultant Radiologist and the YKST Principal Investigator (a Consultant Urologist)at Leeds Teaching Hospitals NHS Trust have developed a series of pathways for flagging in the CT report, based on: 1 - Normal; 2 - benign urological finding; 3 - Indeterminate benign finding (i.e. cholecystitis/pancreatitis); 4 Possible malignancy outside renal tract (2 week wait referral) or AAA (referral to vascular surgery); 5 - Possible renal/urological cancer (2 week wait referral).
The PI will work with the nurse practitioner and administration support employed by YKST for the duration of the scanning period so that they can inform the patients of results and refer patients to the appropriate other specialities: e.g. vascular and HPB surgery There are no further visits of assessments for participants of YKST.
Qualitative interviews and ethnography
We will conduct semi-structured qualitative telephone or remote video interviews within 3 months of the initial study invitation with a purposive sample of both participants who take up the additional abdominal CT scan and those who decline the additional scan. The interviews will explore their views on the acceptability of the combined screening approach, the consent process, the information provided about the additional scan, and their reasons for accepting or declining the scan. We will also explore potential psychological harms, for example, increased anxiety or worry related to the additional scan or the information provided about kidney cancer and other potential abdominal findings. We will draw on the principles of information power when deciding when to cease data collection but anticipate interviewing up to 40 participants. We will purposefully sample participants with the aim to include approximately 20 who took up the additional scan and 20 who did not and to include participants with a range of ages, sex, and abdominal findings. Interviews will be recorded and transcribed for analysis. We expect interviews to last between 30-45 minutes.
To assess the study processes, including ordering the scans, obtaining consent, ensuring only participants consenting to the additional abdominal scan receive it, performing, reporting and reviewing the additional scans and feeding back the results, from the perspective of the healthcare professionals we will also conduct telephone/video link interviews with key individuals involved in the screening pathway. These will include CTAs, research nurses, radiographers, radiologists and the triaging urologist. The interview schedule will cover their views on all stages of the pathway relevant to them.
To explore in more detail the consent and scanning process on the screening vans, we will also conduct an ethnographic study with a researcher spending time on the vans observing the patient flow and processes. The field notes from these observations will be combined with the analysis of the interview data to enable us to identify aspects that worked well and any challenges or potential safety concerns within the proposed combined screening pathway in order to inform a future RCT.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A non-randomised feasibility study of adding non-contrast CT scanning of the abdomen to the CT chest undertaken in the T2 round of YLST. YLST is a two-arm, (1:1) implementation study using a single-consent Zelen's randomised controlled design. Participants have already been randomised to intervention (invitation to an initial telephone-based riskassessment and then, if eligible, for a Lung Health Check (LHC) which is carried out on a mobile van and incorporates LDCT scanning for lung cancer) or usual care (no invitation).
| Arm | Type | Receives |
|---|---|---|
| Abdominal CT Scan | Other | Radiation: Low dose abdominal computed tomography scanA policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer. |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- As YKST will involve only consenting participants of T2 round of YLST the same inclusion criteria for the YLST Lung Health Check at the T0 stage will be used for YKST, namely:
- 30 pack year history of smoking and current smoker or quit within the last 15 years (USPSTF criteria).
- Lung cancer risk of ≥1.51% over 6 years as calculated by the PLCOM2012 score.
- Lung cancer risk of ≥5% over 5 years as calculated by the LLPv2. score.
Key exclusion criteria (5 listed)
- Have undergone CT Thorax within the previous 6 months
- Unable to provide informed consent to study
- Unable to have a chest or abdominal non-contrast CT scan
- Previous diagnosis of kidney cancer
- Have undergone abdominal CT scan in previous 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low dose abdominal computed tomography scanA policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer | Radiation | Abdominal CT Scan |
Primary outcome
The proportion of individuals who take up the offer of an abdominal CT scan
Time frame: At the end of the 18 month recruitment period
The proportion of individuals attending the T2 round of YLST who take up the offer of an abdominal CT scan
The acceptability of the combined lung and RCC screening approach to participants
Time frame: On completion of the patient interview analysis - by the end of the 18 month recruitment period
The acceptability to participants of combined lung and RCC screening by non-contrast CT scanning - ascertained by interviews
The acceptability of the combined lung and RCC screening approach to healthcare professionals
Time frame: On completion of the health care professional interview analysis - by the end of the 18 month recruitment period
The acceptability to healthcare professionals involved in the screening of combining RCC screening by non-contrast CT scanning with lung cancer screening - ascertained by interviews
The additional time required for the combined screening approach
Time frame: On completion of the study process observation analysis - by the end of the 18 month recruitment period
The additional time required for the combined screening approach, including the time to provide information, consent participants, and perform the lengthier CT scan, the time needed by radiologists for reporting the CT scans, and the additional time to review abdominal CT findings
5 secondary outcomes
Estimate of the prevalence of RCC
Time frame: At the end of the 18 month recruitment period
The stage distribution of all RCCs identified, reported as cancer findings with TNM
Time frame: At the end of the 18 month recruitment period
The proportion of participants found to have incidental renal findings
Time frame: At the end of the 18 month recruitment period
The proportion of participants with non-renal findings
Time frame: At the end of the 18 month recruitment period
Estimation of the incidence of RCC
Time frame: At the end of the 18 month recruitment period
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2022.
- Derived from this study: PubMed 40369122Thomas C, Heathcote L, Sun Y, Callister MEJ, Kitt J, Rossi SH, Shinkins B, Usher-Smith JA, Whyte S, Stewart GD; YKST Study Group. Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England. Br J Cancer. 2025 Aug;133(2):239-247. doi: 10.1038/s41416-025-03043-z. Epub 2025 May 14.
- Derived from this study: PubMed 38950010Usher-Smith JA, Masson G, Godoy A, Burge SW, Kitt J, Farquhar F, Cartledge J, Kimuli M, Burbidge S, Crosbie PAJ, Eckert C, Hancock N, Iball GR, Rogerson S, Rossi SH, Smith A, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. Acceptability of adding a non-contrast abdominal CT scan to screen for kidney cancer and other abdominal pathology within a community-based CT screening programme for lung cancer: A qualitative study. PLoS One. 2024 Jul 1;19(7):e0300313. doi: 10.1371/journal.pone.0300313. eCollection 2024.
- Derived from this study: PubMed 36127097Usher-Smith JA, Godoy A, Burge SW, Burbidge S, Cartledge J, Crosbie PAJ, Eckert C, Farquhar F, Hammond D, Hancock N, Iball GR, Kimuli M, Masson G, Neal RD, Rogerson S, Rossi SH, Sala E, Smith A, Sharp SJ, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. BMJ Open. 2022 Sep 20;12(9):e063018. doi: 10.1136/bmjopen-2022-063018.
- YKST twitter accountLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Renal Cell Carcinoma
RecruitingPhase 3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
Active, not recruitingPhase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
Not yet recruitingPhase 2
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
Locally Advanced Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grant D Stewart principal investigator
University of Cambridge
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low dose abdominal computed tomography scan in people with Renal Cell Carcinoma, run by University of Leeds at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of individuals who take up the offer of an abdominal CT scan (time frame: At the end of the 18 month recruitment period). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05005195, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.